ED50 of Propofol Combined with Nalbuphine on the Sedative Effect in Painless Hysteroscopy

Abstract

Introduction: Nalbuphine has gradually become a commonly used clinical analgesic drug for painless hysteroscopy. The aim of our study was to identify the median effective dose (ED50) of propofol combined with nalbuphine for painless hysteroscopy. Methods: Sixty-one patients aged 18–60 years were recruited to undergo elective painless hysteroscopy. Patients were administered 0.1 μg/kg nalbuphine (group A) or 0.2 μg/kg nalbuphine (group B) intravenously 3 min before endoscopic placement. The Dixon sequential method was used with an initial intravenous propofol dose of 2 mg/kg, which varied by 0.5 mg per kilogram. Results: The ED50 of propofol was 1.729 mg/kg (95% confidence interval [CI] 1.526–1.856 mg/kg) in group A and 1.658 mg/kg (95% CI 1.359–1.799 mg/kg) in group B. The 95% effective dose (ED95) of propofol was 2.051 mg/kg (95% CI 1.899–3.331 mg/kg) in group A and 2.020 mg/kg (95% CI 1.849–3.832 mg/kg) in group B. Conclusion: For safety and effective painless hysteroscopic, the ED50 values of propofol combined with nalbuphine were 1.729 mg/kg (0.1 mg/kg nalbuphine) and 1.658 mg/kg (0.2 mg/kg nalbuphine). The recommended dose of nalbuphine is therefore 0.1 mg/kg. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2100042342 (http://www.chictr.org.cn/edit.aspx?pid=66342&htm=4; registration date 19 Jan 2021).